Samsung Bioepis
Entity.
- Evidence
- 20 documents · 7 separate publishers
- Standing
- Added automatically from coverage
- Time
- first seen 7 Sept 2026, last seen 25 Oct 2026
- Measured
- 0% of mentions say something specific about it; the rest only name it
- As of
- 26 Oct 2026
Where this comes from
- Seoul Economic Daily · 2026-10-25 · Samsung Bioepis Targets 20 Biosimilars by 2030, Eyes ADC and Obesity Drugs (opens the source in a new tab)
- The korea Herald News · 2026-10-21 · Samsung Bioepis' first ADC candidate wins FDA Fast Track (opens the source in a new tab)
- Korea Times · 2026-10-21 · Samsung Bioepis wins FDA Fast Track for 1st anticancer drug candidate (opens the source in a new tab)
- Korea Times · 2026-10-20 · Samsung Bioepis secures 10-year exclusive drug supply deal in Brazil (opens the source in a new tab)
- The korea Herald News · 2026-10-20 · Samsung Bioepis secures 10-year biosimilar supply deal in Brazil (opens the source in a new tab)
- Seoul Economic Daily · 2026-10-20 · Samsung Bioepis Wins 10-Year Rare Disease Drug Deal in Brazil (opens the source in a new tab)
- Fierce Pharma · 2026-10-03 · Teva, Samsung Bioepis deepen bonds in pact for up to 6 new biosimilars (opens the source in a new tab)
- BioPharma Dive · 2026-10-03 · Lilly, Foghorn part ways; Wave’s FDA-approved plans (opens the source in a new tab)
- Seoul Economic Daily · 2026-10-01 · Samsung Bioepis, Teva Partner on Two Immunology Biosimilars (opens the source in a new tab)
What is claimed about it
- Corroborated: Reported by three or more sources that did not copy each other.
- Reported by two: Reported by two sources that did not copy each other.
- Samsung Bioepis wins FDA Fast Track for 1st anticancer drug candidate Reported by two · first reported 21 Oct 2026
- Samsung Bioepis secures 10-year exclusive drug supply deal in Brazil Corroborated · first reported 20 Oct 2026